This medicine has been approved very recently and I think it is revolutionary.It will be inclined and serves to reduce cholesterol with only two injections a year.
"Novartis announced today that the European Commission (EC) has approved include for the treatment of adults with hypercholesterolemia or mixed dyslipidemia. This approval is based on the results of a solid Orion Clinical Research Program, where this treatment provided an effective and sustained reductionof low density lipoprotein cholesterol (C-LDL) up to 52% in patients with high C-LDL, despite the maximum tolerance of statin treatment.The 3 months, they are expected to include the results in patients significantly.
Inclisir will be the first small interference RNA (ARNIP) of its class that provides an effective and sustained C-LD reduction for patients with atherosclerotic cardiovascular disease (ASCVD), equivalent to the risk of ASCVD and heterozygous family hypercholesterolemia (HEFH), which are the main drivers of heart attacks, strokes and, ultimately, can cause death.
"Cardiovascular diseases remain the main cause of mortality in Europe, demonstrating the urgent need for innovative treatments for patients fighting to achieve their C-LDL goals. With Inclisir, we are proud to offer the first treatment in their classwhich offers an effective and sustained C-LDL reduction that has the potential to improve the results for people living with ASCVD, ”said Marie-France Tschudin, president of Novartis Pharmaceuticals."
Inclisir will be approved for the treatment of adults with primary hypercholesterolemia (family and non -family heterozygous) or mixed dyslipidemia, as a complement to the diet:
in combination with a statin or statin with other therapies to reduce lipids in patients who cannot achieve C-LDL objectives with the maximum tolerated dose of a statin
alone or in combination with other therapies to reduce lipids in patients who are intolerant to statins or for whom a statin is contraindicated.
The authorization for the marketing of Inclisir will be valid in the 27 EU member countries.Norway, Iceland and Liechtenstein, as members of the European Economic Space (EEE), will make the corresponding decisions based on the CE recommendation.
